All‐cause mortality ‐ short term · health problem or population
It is very uncertain whether summary of findings table ‐ Pharmacological treatment changes all‐cause mortality ‐ short term compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Inpatient mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality ‐ inpatients compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Adverse events—all‐cause mortality · type 1 or type 2 diabetics
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality at 24±6 months · patients with coronary heart disease
Antibiotics leads to higher all‐cause mortality at 24±6 months compared with placebo or no intervention (high certainty).
1 finding from 1 review
ICU mortality · exacerbations of COPD
Antibiotics probably leads to lower all‐cause mortality ‐ ICU patients compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · outpatients withmild disease
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 · non‐hospitalised adults with mild COVID‐19
1 finding from 1 review
All‐cause mortality within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
1 finding from 1 review
All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in all‐cause mortality within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
All‐cause infant mortality at longest · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality All‐cause death · Pregnant women (parity 0‐1)
It is very uncertain whether the intervention changes mortality All‐cause death (very low certainty).
1 finding from 1 review